Chang-Claude Jenny, Popanda Odilia, Tan Xiang-Lin, Kropp Silke, Helmbold Irmgard, von Fournier Dietrich, Haase Wulf, Sautter-Bihl Marie Luise, Wenz Frederik, Schmezer Peter, Ambrosone Christine B
Division of Clinical Epidemiology and Toxicology, German Cancer Research Center, Heidelberg, Germany.
Clin Cancer Res. 2005 Jul 1;11(13):4802-9. doi: 10.1158/1078-0432.CCR-04-2657.
Several DNA repair gene polymorphisms have been described, which affect DNA repair capacity and modulate cancer susceptibility. We evaluated the association of six polymorphisms in the DNA repair genes: XRCC1 (Arg194Trp, Arg280His, and Arg399Gln), APE1 (Asp148Glu), and XPD (Lys751Gln and Asp312Asn), with the risk of acute skin reactions following radiotherapy.
We conducted a prospective study of 446 female patients with breast cancer who received radiotherapy after breast-conserving surgery. Individual genetic polymorphisms were determined using melting point analysis of sequence-specific hybridization probes. The development of acute skin reactions (moist desquamation) associated with DNA repair gene polymorphisms was modeled using Cox proportional hazards, accounting for cumulative biologically effective radiation dose.
Overall, the development of acute toxicity, which presented in 77 patients, was not associated with the genetic variants studied, although the hazard ratios (HR) were generally below 1. Risks were however differential by body mass index. Among normal-weight patients only, both carriers of the APE1 148Glu and the XRCC1 399Gln alleles had decreased risk of acute skin reactions after radiotherapy (HR, 0.49 and 0.51, respectively). The results for XRCC1 were confirmed by haplotype analysis. When considering joint effects, we observed that compared with homozygote carriers of the wild-type allele in both genes, the risk was most strongly reduced in carriers of both APE1 148Glu and XRCC1 399Gln alleles with normal weight [HR, 0.19; 95% confidence interval (95% CI), 0.06-0.56] but not in those with overweight (HR, 1.39; 95% CI, 0.56-3.45; Pinteraction = 0.009).
The XRCC1 399Gln or APE1 148Glu alleles may be protective against the development of acute side effects after radiotherapy in patients with normal weight.
已描述了几种DNA修复基因多态性,它们会影响DNA修复能力并调节癌症易感性。我们评估了DNA修复基因中的六种多态性:XRCC1(Arg194Trp、Arg280His和Arg399Gln)、APE1(Asp148Glu)以及XPD(Lys751Gln和Asp312Asn)与放疗后急性皮肤反应风险的相关性。
我们对446例保乳手术后接受放疗的女性乳腺癌患者进行了一项前瞻性研究。使用序列特异性杂交探针的熔点分析来确定个体基因多态性。采用Cox比例风险模型对与DNA修复基因多态性相关的急性皮肤反应(湿性脱屑)的发生情况进行建模,并考虑累积生物等效辐射剂量。
总体而言,77例患者出现的急性毒性反应与所研究的基因变异无关,尽管风险比(HR)通常低于1。然而,风险因体重指数而异。仅在正常体重患者中,APE1 148Glu和XRCC1 399Gln等位基因的携带者放疗后急性皮肤反应的风险均降低(HR分别为0.49和0.51)。单倍型分析证实了XRCC1的结果。在考虑联合效应时,我们观察到,与两个基因中野生型等位基因的纯合子携带者相比,体重正常的APE1 148Glu和XRCC1 399Gln等位基因携带者的风险降低最为显著[HR,0.19;95%置信区间(95%CI),0.06 - 0.56],但超重者并非如此(HR,1.39;95%CI,0.56 - 3.45;P相互作用 = 0.009)。
XRCC1 399Gln或APE1 148Glu等位基因可能对正常体重患者放疗后急性副作用的发生具有保护作用。